Also, I'd add that ADAMS is a carer-derived assessment.
I can only imagine that there is a degree of enthusiasm and hope from the Carers (possibly with an overflow impact on the patient??) in the performance of these trials, particularly with positive Ph1 results publicly available.
To see no benefit, if you were on the Placebo arm, would be kind of demoralising and even more so if you know someone on the NTI 164 arm that was benefitting.
Ann: Phase II/III autism trial shows further benefits, page-13
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.001(1.89%) |
Mkt cap ! $55.86M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.3¢ | $8.824K | 164.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 2997322 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 263408 | 1 |
View Market Depth
| Last trade - 15.34pm 06/11/2024 (20 minute delay) ? |
| NTI (ASX) Chart |